MD Anderson Cancer Center, The University of Texas
The University of Texas
Dr. Scott Kopetz received his medical degree from Johns Hopkins School of Medicine, USA, after an undergraduate degree in Electrical and Biomedical Engineering at Vanderbilt University, USA. He obtained his residency training in Internal Medicine at Duke University Medical Center, USA, followed by a medical oncology fellowship at M. D. Anderson Cancer Center, USA.
Dr. Kopetz is currently Deputy Chair of the Department of Gastrointestinal (GI) Medical Oncology and Program Leader of the GI Program of the Cancer Center Support Grant at UTMDACC. He serves as Chair of the Colon Cancer Task Force, and is Vice-Chair for Colon Cancer in the NSABP/RTG/GOG (NRG) Cooperative Group. Dr. Kopetz is a leader of the GI Cancer Center Support Grant at M. D. Anderson Cancer Center and the Colorectal Cancer Moonshot, a multi- disciplinary effort to improve the survival of patients with this disease beyond incremental advances.
Dr. Kopetz has developed a translational and clinical trial programme in BRAF-mutated colorectal cancer, which has resulted in addition of combination therapy with a BRAF inhibitor to the current treatment guidelines. He co-led the clinical trial resulting in the FDA-approval of nivolumab for mismatch repair deficient tumors. He is also an innovator in the development and implementation of circulating tumour DNA into clinical management, including interrogation of mechanisms of resistance, evaluation of minimal residual disease, and integration into clinical trial designs.
Friday, 5 July
15:15 – 15:35
Saturday, 6 July
13:05 – 14:35